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Inflammatory bowel disease mainly consisting of ulcerative colitis and Crohn’s disease has been rising gradually during the last
two decades in China. In this review article, we provide the latest epidemiological trends in incidence, prevalence, and mortality
of IBD patients in China and summarize the risk factors and genetic susceptibility of Chinese IBD patients. We also compare these
characteristics to those of IBD patients in Western countries.
1. Introduction
Inflammatory bowel disease (IBD) predominantly consists
of two chronic, often relapsing, immunologically mediated
gastrointestinal disorders: ulcerative colitis (UC) and Crohn’s
disease (CD). The two diseases share many clinical, patho-
genetic, and epidemiologic characteristics, suggesting that
underlying causes may be similar. The chronic inflamma-
tion associated with IBD is related to a sustained immune
response. It is yet to be determined whether this is an appro-
priate response to an unknown pathogen or an inappropriate
response to normal gut contents.
Crohn’s disease primarily affects the terminal ileum and
colon but can involve any portion of the gastrointestinal
tract from mouth to anus. It is often characterized by
discontinuous lesions (“skip lesions”) with inflammation that
can involve the full thickness of the affected portion of bowel
from mucosa to serosa.
Ulcerative colitis commonly involves the rectum, but
it can extend proximally (longitudinally) to affect other
portions of the colon. UC can be classified by extent of disease
as proctitis, left-sided colitis, or pancolitis (when the whole
colon is affected). The inflammatory lesions seen are in a
continuous pattern and only affect the mucosal layers of the
colon without deeper involvement.
In recent decades, the incidence of IBD in traditionally
high incidence areas, such as the United States and Europe,
has been relatively stable. However, the incidence of IBD
has become increased in previously low incidence areas,
including China. Since there is no national IBD registry, epi-
demiological studies are more difficult to perform in China.
To our knowledge, few population-based IBD epidemio-
logical studies are done from Mainland China. This paper
will provide the latest epidemiological trends in incidence,
prevalence, and mortality of IBD in China, summarize risk
factors and genetic susceptibility ofChinese IBDpatients, and




2.1.1. Incidence and Prevalence. It is estimated that UC and
CDprevalence inChina is up to 11.6 cases per 100,000 person-
years and 1.4 cases per 100,000 person-years, respectively [1].
The prevalence may be underestimated from hospital- based
data. Although the prevalence in China is lower than in the
West, these figures increase rapidly. An analysis of 10218UC
cases in China suggests the prevalence for UC increase by
3.08 times from 2506 cases in 1980s to 7512 cases in 1990s
[2]. Compared to 1990, the nationwide ratio of patients with
UC and CD to total hospitalized patients has increased by
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2.11 times [3] in 2001 and by 2.78 times [4] in 2003, respec-
tively. In Hong Kong, the incidence of CD tripled while the
incidence of UC increased slightly over the last 10 years [5].
Lok et al. [6] found that the incidence growth trend of UC
was not obvious but the prevalence of UC tripled during the
period of 1990 to 2006. The latest available incidence rates of
UC inHongKong increased by 6 times over the 2 decades [7].
The above studies from China are almost all hospital-
based small-scale studies, focusing on single region and
inpatient cases, which can lead to underestimate the true
incidence and prevalence due to some underlying selection
bias. However, population-based IBD incidence and preva-
lence data is more reliable in Japan since it has National IBD
registry. It is shown that the incidence of IBD rises tenfold
[8, 9] and the prevalence is also growing in Japan. Yao et al.
[10] have found that the incidence of CD in Japan quadrupled
and the prevalence increased by 4.7-fold from 1986 to 1998. In
Singapore the hospital-based prevalence of CD increased by
5.5-fold, during the past 15 years [11]. In Seoul, Republic of
Korea, the population-based incidence of IBD also increased
tenfold over the past 20 years and the ratio of UC and CD
decreases from 6.8 to 2.3, indicating that the incidence of CD
often overtakes UC [12].
Incidence and prevalence of UC and CD from selected
geographic regions are shown in Tables 1 and 2, which suggest
that the incidence of IBD increases steadily in East Asian
countries, although it is lower than that in Europe and the
United States [13–15]. In theWestern countries, the incidence
of IBD has been growing rapidly since World War II and
has stabilized and even declined in some areas currently. It
is anticipated that the incidence difference between Asian
and Western countries will decrease and may eventually
disappear.
2.2. Mortality. A retrospective analysis of 3100 inpatients
suggested that UC mortality of mainland China was 0.6%
over the 5 years follow-up period [3]. A long-term study from
Hong Kong showed that the 10-year and 20-year cumulative
survival rates in patients with UC in Hong Kong are 95%
and 94%, respectively [7]. Another long-term study in Japan
showed that the cumulative survival rates decreased year by
year and decreased to 96.2% by the 10th year [19]. From
the Korean studies involving 304UC cases, the cumulative
survival rates after 1, 5, 10, and 15 years are 100%, 99.4%,
97.4%, and 89.9%, respectively [20]. The 10-year cumulative
survival rate (91.1%–93%) in Asian patients with UC was
roughly equal to Western countries, and the mortality rate
did not differ from the general population [20]. There are no
large-scale long-term follow-up studies frommainlandChina
population; the reported mortality rate from Hong Kong is
consistent with Japan and Republic of Korea.
Thus far, mortality data for CD in China remains unpub-
lished. A Japanese cohort study involving 276CD patients
[21] reported the cumulative survival rates of 98.9% at 5 years,
98.1% at 10 years, 97.7% at 15 years, and 94.9% at 20 years
after the onset of disease. This study indicated a small but
persistent decline in relative survival over time, consistent
with most CD survival studies in the Western world [22].
In addition, the survival studies in the Western countries
suggest that age of diagnosis older than 40 years is an
independent risk factor for increased mortality.
2.3. Colorectal Cancer. Compared to Western studies of 3–
5% [22], the incidence of colorectal cancer (CRC) among
ChineseUCpatients had been reported to be lower. However,
results varied from study to study. A retrospective analysis
of 3100 hospitalized UC patients suggests that the incidence
of CRC is 0.4% [3]. Another retrospective analysis of 513
hospitalized IBD patients, including 242UC and 271 CD,
shows that 4UC patients (1.65%) developed cancer and 4
(1.65%)were confirmedwith precancerous lesion, but none of
the 271 CD patients developed cancer [23]. This risk is lower
than results from a meta-analysis [24] of CRC risk among
Western UC patients of 1.6% at 10 years, 8.3% at 20 years, and
18.4% at 30 years, and this has been thought to be due to a
relatively shorter duration of disease and a lower population
risk of sporadic CRC.
2.4. Age and Gender Distribution. Age and gender distri-
bution of UC and CD from different regions are shown in
Table 3. In China, the mean age of onset with CD is about 10
years earlier than UC, just as in Japan, Republic of Korea, and
Western countries. But the peak age of IBDonset inMainland
China is older than that in other countries. Although Asian
studies reported a similar peak age of onset for both UC and
CD among Japan, Republic of Korea, and Western countries,
the second smaller peak is more likely to occur in Western
countries [22], with the exception of Japan, which has a
second smaller peak age on 60–64 years old [21]. Latest study
suggests a second smaller peak age on 45–54 years old in
Hong Kong [7], but not found in Mainland China.
As shown in Table 3, in China, there were more male
than female patients with CD and UC [4, 5]. In studies
from Western countries, there is rarely gender distribution
difference. But the latest study [17] shows that in high
incidence areas, UC occurs more frequently in men and CD
occurs 20% to 30% more frequently in females while in low
incidence areas, CD has been reported more frequently in
men.
3. Risk Factors
3.1. Familial Aggregation. A family history of UC in China
was previously noted to be uncommon, with a frequency
ranging from 4.4% to 6.7% in Mainland China [25] and with
a frequency of 2.7% in Hong Kong [6]. A recent study from
Hong Kong [5] reported a familial occurrence of CD at 0%,
considerably lower than the reported rates from Western
series ranging from 10% to 20% [25]. In Asia, the familial
occurrence of CD is ranging from 1.6% to 4.5% [22], which is
similarly lower compared to that in theCaucasian population.
Recent studies from China have reported a similar lower
familial aggregation rate for UC, ranging from 1.5% to
5.6% [22]. Within East Asia, Japan had reported a familial
occurrence of CD at 2.8% [8], and Republic of Korea had
also reported a familial occurrence of CD at 2.6% and UC
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Table 1: Incidence and prevalence (per 100,000) of IBD in China.
Region Study period UC CD
Incidence Prevalence Incidence Prevalence
1997 0.35 2.30
Hong Kong [6] 2001 0.85 4.90
2006 0.40 6.99
1986–1989 0.8 0.3
Hong Kong [5] 1990–1992 1.2 0.4
1999–2001 1.0
1986–1988 0.3
Hong Kong [7] 2004–2006 1.8
2006 2.1 26.5
Hong Kong [16] 2011-2012 1.66 1.31
Macau [16] 2011-2012 1.00 0.60
Mainland China [1, 4] 1950–2000 0.28 1.38
1990–2003 11.6
China (Chengdu) [16] 2011-2012 0.43 0.14
China (Guangzhou) [16] 2011-2012 2.22 1.22
China (Wuhan) [17] 2010-2011 1.59 0.56
China (Xian) [16] 2011-2012 0.42 0.07
Table 2: Incidence and prevalence (per 100,000) of IBD from Europe, America, and other Asian Pacific countries.
Region Study period UC CD
Incidence Prevalence Incidence Prevalence
Japan [8] 1965 0.08 5.5 0.01 0.88
1986 0.6 2.9
Japan [10] 1991 0.9 6.3
1998 1.2 13.5
Japan [9] 1991 1.95 18.1 0.51 5.85
Japan [18] 2005 63.6 21.2
1986–1990 0.34 0.05
Korea [12] 1991–1995 0.87 0.22
1996–2000 1.74 7.6 0.52
2001–2005 3.08 30.9 1.34 11.2
1990 1.3
Singapore [11, 16] 2004 7.2
2011-2012 0.61 0.40
America [13, 14] 1984–1993 8.3 229.0 6.9 144.1
Europe [15] 1991–1993 10.4 5.6
Asia [1] 2004 1.0–2.0 4.0–44.3 0.5–1.0 3.6–7.7
Australia [17] 2007-2008 11.2 17.4
New Zealand [17] 2004 7.6 16.5
at 2.9% [12]. The lower familial clustering rates observed in
China, Japan, and Republic of Korea are related to the low
prevalence of IBD in these countries. In a recent study from
Republic of Korea [12], a twofold increase (from 1.3% in 2001
to 2.7% in 2005) in the frequency of a positive family history
was observed, while there was a corresponding twofold rise
(from 19.81 per 100,000 in 2001 to 42.11 per 100,000 in 2005) in
the prevalence of IBD. This finding suggests that the familial
clustering rate of IBD may rise with time in parallel with the
increase in prevalence of IBD.
3.2. Cigarette Smoking. Since the first widely publicized
report of an inverse association between ulcerative colitis
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Mainland China [3, 4] 40–49 44.1 1.34 : 1 31–40 37.7 1.67 : 1
Hong Kong [6] 30–39 40.6 1.34 : 1




37X 1.07 : 1
China [25] 37.2 Mainland32.1 Hong Kong
2.5 : 1
Japan [10] 30–35 1.15 : 1 30–35 2.3 : 1
Korea [12] 35X 0.99 : 1 21.5X 2.83 : 1
Western countries [22] 30–40 20–30
∗The first peak age of onset, ∗∗the second peak age of onset, and Xmedian age.
and cigarette smoking, many studies have confirmed this
unusual finding. A Chinese case-control study in China also
demonstrated that smoking reduces the risk of UC [18].
However, an analysis of 10218UC cases in China suggests
that smoking does not correlate with the severity of UC,
but ex smokers are more likely to encounter UC recurrence
than those who continued to smoke [2]. In another study
from Europe [26], smokers with ulcerative colitis who quit
smoking had more active disease, more hospitalizations,
and greater need for corticosteroids or azathioprine com-
pared with those who continued to smoke. The mechanism
of action for this unusual association remains unclear—
potentially important effects of nicotine on rectal blood
flow, colonic mucus, cytokines, and eicosanoids have been
reviewed elsewhere.
It has been confirmed that smoking is an independent risk
factor for CD. It was similarly shown in a Chinese population.
A case-control study fromChina [27] has implicated cigarette
smoking as a risk factor for CD. Another study from Japan
[8] suggests that former smokers are also at risk, but the
magnitude is less than that for current smokers. Smoking
can influence the clinical course of CD. Patients with CD
who smoke are more likely to have ileal than colonic or
ileocolonic involvement, and smokers are more likely to have
CD with penetrating or stricture disease instead of pure
inflammatory CD. Continued cigarette smoking following
surgical resection increases the risk of recurrent disease.
3.3. Appendectomy. There is only one case-control study
involving 96 cases accessed, which suggests that appendec-
tomy has no relation to the development of UC [18]. A
meta-analysis [28] of 17 case-control studies involving almost
3600 cases and over 4600 controls demonstrated a 69%
risk reduction for the development of UC. Several Asian
case-control studies had reported a similar protective effect
of appendectomy against UC, with ORs ranging from 0.11
to 0.38 [22]. In a multicenter study from Japan [28], UC
patients diagnosed after appendectomy also tended to have
delayed onset, fewer relapses, and fewer colectomy compared
to patients with an intact appendix.
In contrast, most studies [29] have suggested that appen-
dectomy is a risk factor for CD development. However,
children who underwent appendectomy before the age of 10
years oldwere less likely to developCD.Thosewho developed
CD following a surgery for perforated appendicitis had a
more aggressive form, requiring intestinal resection at least
twice as frequently as others. It remains controversial, with a
recent large population-based study pointing to a diagnostic
bias as the likely explanation for the association.There is only
one case-control study involving 51 CD cases in China [27],
which did not reveal the association of appendectomy and
CD.
3.4. Mycobacterial Infection. The association between myco-
bacterial infection and IBD remains controversial. A case-
control study from China suggests that gastrointestinal and
respiratory infection during childhood are risk factors for the
development of CD [27]. Although several open-label studies
of antibiotic regimens with antimycobacterial activity have
suggested clinical improvement, the results from randomized
clinical trials are less compelling [30–32].
3.5. Diet. No consensus on the association between diet and
IBD has emerged because of the poor recall of diet and the
possibility that diet was subconsciously altered even before
formal diagnosis because of gastrointestinal symptoms. The
most consistent association noted in dietary studies has been
the link between increased sugar intake and IBD, especially
CD. There is yet no published study on the association of
high sugar intake and IBD in China. Only several small-
scale case-control studies [18, 33] suggest that both high
dietary fiber intake and low fat intake are protective factors for
IBD. In Western countries, some epidemiologic studies have
implicated that low sugar and low fat and high fiber dietary
may be protective against the development of IBD. A very
well spurious finding could be that patients with IBD related
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bowel strictures and diarrhea may restrict intake of fiber and
fat.
3.6. Other Risk Factors. Two case-control studies conducted
within Mainland China have suggested an increased risk
of IBD in women who take oral contraceptive or NSAID
[18, 27]. Other putative risk factors for IBD, such as perinatal
and childhood factors (breastfeeding, domestic hygiene, and
infection), measles infection, or vaccination remain contro-
versial [29], and they have not been formally investigated in
Chinese cohorts.
4. Molecular Epidemiology
Descriptive epidemiologic studies have highlighted familial
aggregation as a risk factor for IBD, suggesting the genetic
susceptibility plays an important role in developing IBD.
Identifying these susceptibility genes and gene differences for
IBD betweenAsian andWhite populationsmay explain some
of the observed epidemiologic differences.
Three single nucleotide polymorphisms (SNPs) of the
NOD2/CARD15 gene have been first identified to be inde-
pendently associated with the development of CD in Cau-
casians. Nucleotide-binding oligomerization domain protein
2/caspase recruitment domain protein 15 (NOD2/CARD15)
mutations, may account for up to 20% of CD in the white
and Jewish population [34, 35]. However, these associations
were not found in studies from China (including Zhejiang,
Jiangsu, and Guangdong provinces) [36], Hong Kong [37],
Japan, Republic of Korea, Israeli Arabs and Turkey. A case-
control study [38] involving 148 cases in Guangdong, China,
has found thatNOD2P268Smutationmay be associatedwith
the age of onset, location, and complication of CD in Chinese
population.
Prior studies [22] had confirmed that polymorphisms in
the tumor necrosis factor (TNF) genes and HLA genes are
susceptible to UC. A case-control study [39] involving 402
cases in Zhejiang province, China, has found that TNF-308A
is associated with the development of UC in Chinese Han
population. Another two case-control studies showed that
HLA-DR gene polymorphism is associated with the pheno-
type of UC and also showed that HLA-DR2 allele, HLA-
DRB1∗15 allele in Chinese Han population of Jilin province
[40], and MICB 0106 allele in Chinese Han population of
Hubei province [41] may be the susceptibility genes of UC.
Thus far, molecular epidemiology data for IBD in China
remains limited to sporadic case-control cohorts. Further
nationwide studies involving multiraces are called to deter-
mine if the susceptibility genes play more important role in
the development of IBD among Chinese populations.
5. Conclusion
In the past two decades, the number of IBD in China is
growing rapidly, although it is still lower compared with the
incidence data from the Western country. We hypothesize
that the rising incidence of IBD in China is probably due
to the combination of westernization of lifestyle, healthcare
expansion/improvement, and higher recognition of the dis-
ease. As the incidence increases, the differences between
China and Western population show up gradually. There is
less familial aggregation, lower incidence of CRC in IBD, and
less NOD2/CARD15 gene mutation in Chinese population
compared to the Western population. Further studies to
identify unique genetic susceptibilities and environmental
influences in Chinese population are needed.
The collection of accurate epidemiologic data in China
has been hampered by the lack of nationwide IBD registry.
Most retrospective hospital-derived data may lead to an
underestimate of the incidence rate and an overestimate of
disease severity. It is difficult to know whether the current
epidemiology data mainly from single province and for
short period can represent the whole Chinese population
because different parts of China are undergoing different
rates of industrialization and westernization.The nationwide
population-based epidemiologic study over a long period is
called urgently.
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